Cabaletta Bio, Inc.
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T cell products to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses. At Cabaletta, we are committed to transforming the treatment of B cell-mediated autoimmune diseases by utilizing our innovative and modular CAAR T platform to develop highly specific products that offer the potential for deep, durable and potentially curative responses for patients with autoimmune diseases. We are a clinical-stage biotechnology company working to develop and launch potentially breakthrough engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
The Final Act for Autoimmune Disease
What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.
On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patients with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABA™) platform is focused on eliminating pathogenic B cells that express autoantibodies, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABA™ platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal pemphigus vulgaris (mPV). We have advanced several other high-priority targets into discovery and preclinical testing, including five announced and two unannounced programs.
Our Mission
To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.
Our Vision
To develop and launch the first targeted cellular therapies for patients with autoimmune diseases. When we succeed, we will be:
- Champions to patients
- Valued partners to physicians
- Preferred collaborators to scientists and partners
- Family to each other
- Value-added providers to payors
- Trusted, transparent, and reliably providing a fair return to our investors
Our Values
- Prioritize the patient
- Listen to the data
- Serve the team
- Improve every day
- Pursue excellence and persevere
- Be authentic, vulnerable, and courageous
- Embrace differences, demand equity and inspire trust
- Do the right thing
Orchestrating the Future of Autoimmune Therapy
Orchestrating the Future of Autoimmune Therapy
We aim to leverage our CABA™ platform to rapidly advance new CAAR T cell therapies for patients with B cell-mediated autoimmune diseases.
Our strategy is to:
- Achieve clinical proof-of-concept for DSG3-CAART in patients with mucosal pemphigus vulgaris.
- Advance a portfolio of high potential targets based on our proprietary CABA™ platform.
- Continue to expand our established intellectual property position.
- Leverage our leadership position with CAAR T therapies as well as our robust talent and team-oriented culture to build a fully integrated cell therapy company focused on autoimmune diseases.
- Build on a foundation of clinically validated CAR T manufacturing processes with innovative advances to enhance the profile of products for patients.